APA (7th ed.) Citation

Blauvelt, A., Lomaga, M., Burge, R., Zhu, B., Shen, W., Shrom, D., . . . Pinter, A. (2020). Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial. Journal of Dermatological Treatment, 31(2), 141. https://doi.org/10.1080/09546634.2019.1587146

Chicago Style (17th ed.) Citation

Blauvelt, Andrew, Mark Lomaga, Russel Burge, Baojin Zhu, Wei Shen, David Shrom, Martin Dossenbach, and Andreas Pinter. "Greater Cumulative Benefits from Ixekizumab Versus Ustekinumab Treatment over 52 Weeks for Patients with Moderate-to-severe Psoriasis in a Randomized, Double-blinded Phase 3b Clinical Trial." Journal of Dermatological Treatment 31, no. 2 (2020): 141. https://doi.org/10.1080/09546634.2019.1587146.

MLA (9th ed.) Citation

Blauvelt, Andrew, et al. "Greater Cumulative Benefits from Ixekizumab Versus Ustekinumab Treatment over 52 Weeks for Patients with Moderate-to-severe Psoriasis in a Randomized, Double-blinded Phase 3b Clinical Trial." Journal of Dermatological Treatment, vol. 31, no. 2, 2020, p. 141, https://doi.org/10.1080/09546634.2019.1587146.